Press Releases

Date Title and Summary Additional Formats
Toggle Summary Radius Exceeds 2018 Financial Guidance and Provides Business Update at the 37th Annual J.P. Morgan Healthcare Conference
WALTHAM, Mass. , Jan. 07, 2019 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq: RDUS), today announced that it has exceeded its 2018 financial guidance with full-year TYMLOS® U.S. net sales surpassing the upper range of $95 to $98 million . Radius closed 2018 with a $235 million cash, cash
View HTML
Toggle Summary Radius Health to Present at the 37th Annual J.P. Morgan Healthcare Conference
WALTHAM, Mass. , Jan. 02, 2019 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq: RDUS), today announced that President and Chief Executive Officer, Jesper Høiland , will present a corporate update at the 37 th Annual J.P. Morgan Healthcare Conference on Monday, January 7, 2019 at 1:30 pm PST at the
View HTML
Toggle Summary Radius Health Provides Updates on its Oncology Programs and Announces Scientific Presentations at 2018 San Antonio Breast Cancer Symposium (SABCS)
Phase 3 elacestrant study has opened for enrollment Fast Track designation from the FDA for the Phase 3 study population Elacestrant pre-clinical data demonstrates further evidence of anti-tumor activity in breast cancer models with resistance to CDK 4/6 inhibitors and ESR1 mutations RAD140 Phase 1
View HTML
Toggle Summary Radius Health Announces Third Quarter 2018 Operating Results and Financial Guidance for FY 2018 and FY 2019
TYMLOS® U.S. net sales continued to increase in the third quarter of 2018, totaling $27.6 million. 2019 Medicare Part D coverage for TYMLOS increased from 44% to 64%  Elacestrant Phase 3 study to target a broader patient population, comprised of 2 nd and 3 rd line ER+ mBC, with potential for
View HTML
Toggle Summary Radius Health to Announce Third Quarter 2018 Financial Results, Host Conference Call and Live Webcast on November 1, 2018
WALTHAM, Mass. , Oct. 12, 2018 (GLOBE NEWSWIRE) -- Radius Health (Nasdaq: RDUS) announced today that it will release its third quarter financial results on Thursday, November 1, 2018 . The Company will host a conference call and live audio webcast at 8:00 a.m.
View HTML
Toggle Summary Radius Health Announces Latest 2019 Medicare Part D Coverage for TYMLOS® (abaloparatide) Injection
TYMLOS is now covered for 64% of Medicare Part D insured lives WALTHAM, Mass. , Oct. 03, 2018 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq: RDUS), a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing innovative endocrine therapeutics in
View HTML
Toggle Summary Radius Health to Present at the Leerink Partners Oncology Roundtable Series
WALTHAM, Mass. , Sept. 28, 2018 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq: RDUS) announced today that Jesper Høiland, President and CEO and Charles Morris , Chief Medical Officer of the Company will present a corporate update at the Leerink Partners Oncology Roundtable Series on Wednesday,
View HTML
Toggle Summary Radius Health to Present Data on Abaloparatide at ASBMR 2018 Annual Meeting
WALTHAM, Mass. , Sept. 24, 2018 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq: RDUS), a science-driven fully integrated biopharmaceutical company committed to developing and commercializing innovative endocrine therapeutics in the areas of osteoporosis and oncology, today announced it will
View HTML
Toggle Summary Radius Health to Present at the Morgan Stanley 16th Annual Global Health Care Conference
WALTHAM, Mass. , Sept. 11, 2018 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq: RDUS) announced today that Jesper Høiland, President and CEO, and Pepe Carmona , Chief Financial Officer of the Company, will present a corporate update at the Morgan Stanley 16th Annual Global Health Care Conference
View HTML
Toggle Summary Radius Health Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass. , Sept. 06, 2018 (GLOBE NEWSWIRE) -- Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq:RDUS) today announced that the Company’s Board of Directors granted Dr. Charles Morris , in connection with his appointment as the Company’s Chief Medical Officer, an option to purchase
View HTML